Results 51 to 60 of about 4,520 (170)

A Phase 1 Multiple‐Dose, Open‐Label, Pharmacokinetic Study of Nirmatrelvir/Ritonavir in Healthy Lactating Women

Clinical and Translational Science, Volume 19, Issue 5, May 2026.
ABSTRACT In accordance with the Centers for Disease Control and Prevention recommendations, pregnant women and those with a recent pregnancy (i.e., lactating) are considered at high risk of developing severe COVID‐19 and qualify for treatment with nirmatrelvir/ritonavir.
Jacqueline Gerhart, Narayan Cheruvu, Kathleen Pelletier, Kyle Matschke, Haihong Shi, Josué Kunjom Mfopou, Jennifer Hammond, Ravi Shankar P. Singh   +7 more
wiley   +1 more source

Evaluating Drug Interaction Risks: Nirmatrelvir & Ritonavir Combination (PAXLOVID^®) with Concomitant Medications in Real-World Clinical Settings

Pathogens
Background: This research article delves into the battle against the COVID-19 pandemic, focusing on the efficacy and, particularly, the safety of the combination of nirmatrelvir with ritonavir, which is found in the pharmaceutical product Paxlovid®. This
Petra Zatovkaňuková, Dalibor Veselý, Jiří Slíva   +2 more
doaj   +1 more source

2‐Phenylquinolines Exhibit Anti‐Severe Acute Respiratory Syndrome Coronavirus‐2 Activity Through the Nonstructural Protein 13 Helicase Inhibition

ChemMedChem, Volume 21, Issue 7, 14 April 2026.
A SAR study led to the identification of new 2‐phenylquinoline‐based derivatives that exhibit anti‐Severe Acute Respiratory Syndrome Coronavirus‐2 (SARS‐CoV‐2) activity by acting as ATP‐competitive inhibitors of nonstructural protein 13 (nsp13) helicase.
Giada Cernicchi, Maria Giulia Nizi, Roberta Emmolo, Leentje Persoons, Manon Laporte, Dirk Jochmans, Isabella Romeo, Giacomo Pepe, Ciro Milite, Pietro Campiglia, Jacopo Spezzini, Alma Martelli, Simone Brogi, Francesca Esposito, Tommaso Felicetti, Serena Massari, Giuseppe Manfroni, Stefano Sabatini, Gianluca Sbardella, Stefano Alcaro, Johan Neyts, Angela Corona, Enzo Tramontano, Steven De Jonghe, Oriana Tabarrini   +24 more
wiley   +1 more source

Structure‐ and Ligand‐Based Discovery of Novel 3‐Chymotrypsin‐Like Protease Nonpeptidomimetic Hits

ChemMedChem, Volume 21, Issue 7, 14 April 2026.
A multistep virtual screening cascade, integrating shape‐based, ensemble docking, and quantitative structure–activity relationship (QSAR) models, was employed to screen 1.5 million compounds. This funnel identified a novel 3‐chymotrypsin‐like protease (3CLpro) inhibitor, LabMol‐499, which was experimentally validated using a Förster Resonance Energy ...
Sabrina Silva‐Mendonça, Donald Seanego, Christopher Jurisch, Melina Mottin, Flávia Nader Motta, Beatriz S. A. Rodrigues, Gilberto S. M. Junior, Alexandra Maria dos Santos Carvalho, Fábio Muniz de Oliveira, Sunniva Sigurdardóttir, Per Sunnerhagen, Izabela Marques Dourado Bastos, Richard Gessner, Kelly Chibale, Carolina Horta Andrade   +14 more
wiley   +1 more source

Insights from a community-based survey on factors influencing acceptance and uptake of Paxlovid (nirmatrelvir and ritonavir) as a COVID-19 antiviral medication in Singapore

BMC Public Health
Introduction Antiviral treatment can reduce the burden of COVID-19. But utilisation can be suboptimal, even in a setting like Singapore where it is fully subsidized for those with selected medical conditions and older adults (≥ 50 years).
Sheng En Alexius Matthias Soh, Wei Ling Brenda Ong, Tun-Linn Thein, Konstadina Griva, I.-Cheng Mark Chen   +4 more
doaj   +1 more source

COVID‐19 Antiviral Treatment: Examining Knowledge, Access, Trust in Sources of Information and Willingness to Use Among Essential Workers: A Cross‐Sectional Survey of Cohort Participants

Health Science Reports, Volume 9, Issue 4, April 2026.
ABSTRACT Background and Aims Despite evidence of effectiveness, oral antivirals for COVID‐19 are underused, with significant variation across populations. This study examines COVID‐19 treatment awareness, knowledge, access, trusted sources, and willingness to use among diverse essential workers in Tennessee during May 18, 2023–June 1, 2024.
Jenae Sanders, Jade James‐Gist, Melisa M. Shah, Nathan Graff, Olivia Almendares, Tiffany Israel, Yuwei Zhu, Bryan Blette, Sarah Hamid, Hope King, H. Keipp Talbot, Carlos G. Grijalva, Melissa Briggs‐Hagen   +12 more
wiley   +1 more source

COVID‐19 Prophylactic Effect of Bromhexine Hydrochloride

Immunity, Inflammation and Disease, Volume 14, Issue 4, April 2026.
ABSTRACT Introduction Despite extensive efforts to identify effective treatments for COVID‐19, preventive strategies remain essential. Bromhexine hydrochloride (BRH), an over‐the‐counter mucolytic with potential TMPRSS2 inhibition, may reduce viral entry and thus serve as a prophylactic agent.
Vanyo Mitev, Tsanko Mondeshki, Ani Miteva, Konstantin Tachkov, Violeta Dimitrova   +4 more
wiley   +1 more source

Native American Pregnant and Postpartum People's Experiences of Discrimination During Perinatal Care: A Qualitative Study

BJOG: An International Journal of Obstetrics &Gynaecology, Volume 133, Issue 5, Page 1026-1036, April 2026.
ABSTRACT Objective Indigenous pregnant and postpartum people are more likely to experience severe maternal morbidity (SMM) and mortality than non‐Indigenous groups. We sought to explore how community and societal factors, culture, and resilience impact Native American individuals' pregnancy experiences and might offer insights to address inequities in ...
Jennifer L. Murray, Heather Tanana, Torri D. Metz, Reham Perry, Elisabeth R. Kimball, Patrick Galyean, Susan Zickmund, Michael W. Varner, Michelle P. Debbink   +8 more
wiley   +1 more source

Antivirals Targeting Coronavirus RNA‐Dependent RNA Polymerase and Main Protease: From Mechanisms of Action to Outcomes in COVID‐19 Clinical Trials

Microbial Biotechnology, Volume 19, Issue 4, April 2026.
The target sites of COVID‐19 antivirals discussed in the present opinion paper, namely the RNA dependent RNA polymerase Nsp12 and of the main viral protease Nsp5, are indicated by a red star in the overview of the replication cycle of coronavirus SARS‐CoV‐2.
Harald Brüssow
wiley   +1 more source

Comparative evaluation of authorized drugs for treating Covid‐19 patients

Health Science Reports, 2022
Background and Aims Vaccines are the first line of defense against coronavirus disease 2019 (Covid‐19). However, the antiviral drugs provide a new tool to fight the Covid‐19 pandemic.
Towhidul Islam, Moynul Hasan, Mohammad Saydur Rahman, Md. Rabiul Islam   +3 more
doaj   +1 more source